Michael Barbella, Managing Editor02.21.23
SIMPLEX QUANTUM Inc. is ¥550 million richer, having raised Series A funding from Simplex Holdings Inc., and the Technology Ventures No. 5 Investment Limited Partnership managed by ITOCHU Technology Ventures (ITV), and ITOCHU Corporation.
This money will help support SIMPLEX QUANTUM’s clinical trial currently underway for submission to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) as well as future U.S. Food and Drug Administration (FDA) approval processes.
“SIMPLEX QUANTUM’s heart failure detection AI technology has generated interest from the healthcare industry, academia, and consumers. We expect SIMPLEX QUANTUM’s technologies and achievements will help bring synergies to our expansion into non-financial industries, and we look forward to developing new business opportunities that maximize both companies’ strengths going forward,” Simplex Holdings President Hideki Kaneko stated.
SIMPLEX QUANTUM late last year announced receipt of a U.S. patent for technology designed to reduce medical staff labor in determining heart failure stage. The system references data from hundreds of thousands of electrocardiograms (ECGs) and determines heart failure stage using deep learning methodology. The company's technology has not yet received FDA clearance for marketing in the United States. However, with its pre-submission application to the FDA, the company initiated the regulatory pathway to market its technology as a U.S. medical device.
“This system synergizes advanced analysis technology, access to massive amounts of clinical data, and the expertise of healthcare specialists. We support SIMPLEX QUANTUM’s plans to become a game changer in the medical industry while making the most of cooperation with our medical network to supply clinical data for technology verification,” ITV Senior Vice President Takeshi Abe said.
SIMPLEX QUANTUM also recently completed a second U.S. patent registration for a system designed to accurately authenticate an individual’s electrocardiogram (ECG) waveform data.
“This breakthrough in detecting heart failure from an ECG is designed to reduce clinicians’ workload and the cost of care. We support the global expansion of SIMPLEX QUANTUM with access to our network,” said Hiroshi Kajiwara, executive officer of the Information and Communications Division of ITOCHU Corporation.
Founded in 2014, SIMPLEX QUANTUM develops technology in collaboration with partners including the University of Tokyo Hospital and Japan’s Agency for Medical Research and Development.
Founded in 2000, ITV is the venture capital arm of ITOCHU Corporation, one of the world's largest companies with offices in more than 60 countries. ITV leverages the resources of ITOCHU to help information technology companies grow. Previous funding successes of the ITOCHU group include Siebel Systems, NVIDIA, Openwave, and Aruba Networks.
With approximately 100 bases in 62 countries, ITOCHU is one of the leading trading corporations covering various sectors. As ITOCHU expanded its ICT business in the medical and healthcare field, ITOCHU successfully invested in DOCQUITY in 2019, the largest healthcare professions platform in Southeast Asia. The total investment amount is US$38 million.
This money will help support SIMPLEX QUANTUM’s clinical trial currently underway for submission to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) as well as future U.S. Food and Drug Administration (FDA) approval processes.
“SIMPLEX QUANTUM’s heart failure detection AI technology has generated interest from the healthcare industry, academia, and consumers. We expect SIMPLEX QUANTUM’s technologies and achievements will help bring synergies to our expansion into non-financial industries, and we look forward to developing new business opportunities that maximize both companies’ strengths going forward,” Simplex Holdings President Hideki Kaneko stated.
SIMPLEX QUANTUM late last year announced receipt of a U.S. patent for technology designed to reduce medical staff labor in determining heart failure stage. The system references data from hundreds of thousands of electrocardiograms (ECGs) and determines heart failure stage using deep learning methodology. The company's technology has not yet received FDA clearance for marketing in the United States. However, with its pre-submission application to the FDA, the company initiated the regulatory pathway to market its technology as a U.S. medical device.
“This system synergizes advanced analysis technology, access to massive amounts of clinical data, and the expertise of healthcare specialists. We support SIMPLEX QUANTUM’s plans to become a game changer in the medical industry while making the most of cooperation with our medical network to supply clinical data for technology verification,” ITV Senior Vice President Takeshi Abe said.
SIMPLEX QUANTUM also recently completed a second U.S. patent registration for a system designed to accurately authenticate an individual’s electrocardiogram (ECG) waveform data.
“This breakthrough in detecting heart failure from an ECG is designed to reduce clinicians’ workload and the cost of care. We support the global expansion of SIMPLEX QUANTUM with access to our network,” said Hiroshi Kajiwara, executive officer of the Information and Communications Division of ITOCHU Corporation.
Founded in 2014, SIMPLEX QUANTUM develops technology in collaboration with partners including the University of Tokyo Hospital and Japan’s Agency for Medical Research and Development.
Founded in 2000, ITV is the venture capital arm of ITOCHU Corporation, one of the world's largest companies with offices in more than 60 countries. ITV leverages the resources of ITOCHU to help information technology companies grow. Previous funding successes of the ITOCHU group include Siebel Systems, NVIDIA, Openwave, and Aruba Networks.
With approximately 100 bases in 62 countries, ITOCHU is one of the leading trading corporations covering various sectors. As ITOCHU expanded its ICT business in the medical and healthcare field, ITOCHU successfully invested in DOCQUITY in 2019, the largest healthcare professions platform in Southeast Asia. The total investment amount is US$38 million.